Vivatides Therapeutics

Raised $54M in a Series A round, announced 10 April 2026.

Latest round Series ACountry ChinaSector Health

Round

Series A to fund IND-enabling studies for siRNA and ASO programs.

Amount: $54M
Stage: Series A
Announced: 10 April 2026
Lead: Qiming Venture Partners
Other investors: Highlight Capital, TF Capital, Apricot Capital
Use of funds: Series A to fund IND-enabling studies for siRNA and ASO programs.
Checked: Announced by the company
Sources: Vivatides Therapeutics announces oversubscribed $54M Series A biospace.com
Vivatides Therapeutics announces oversubscribed $54M Series A ventureburn.com

Develops RNA therapeutics that reach tissues beyond the liver

How much has Vivatides Therapeutics raised?

Vivatides Therapeutics raised $54M in a Series A round, announced on 10 April 2026.

Who invested in Vivatides Therapeutics?

Qiming Venture Partners led. Investors include Qiming Venture Partners, Highlight Capital, TF Capital and Apricot Capital.